In our oncology focus month, Ryan McGuire takes a look at the impact of clinical development on cancer drug ... phase 1, phase 2 and phase 3 clinical trial." Based on the report's trial data, it ...

Pre-Clinical Drug Discovery Services Market to grow through 2035, driven by rising chronic diseases and increased outsourcing of early-stage R&D.

Learn how AI in drug discovery is revolutionizing therapeutic development and addressing challenges in cell and gene therapy.

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fu ...

Fortrea forecasts revenue and EBITDA declines for 2025. With a $477.16M market cap, financial improvement could drive stock ...

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s ...

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

Artificial Intelligence (AI) is no longer a futuristic idea in healthcare; it is reshaping the industry right now, and 2025 ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for develo ...

In 2014, the clinical development success rate stood at 10.4%; just over one in every 10 drugs that entered a Phase I clinical ... clinical trials in a more cost-effective manner.